CBD taken with an antidepressant has not been shown to cause memory loss, but CBD can slow the metabolism of some antidepressants and increase drug exposure. Ask whether CBD could raise your antidepressant level and whether confusion or memory changes require a separate evaluation, especially for low blood sodium. Drug metabolism is the process the body uses to break down and clear medicines. Available FDA labeling and controlled studies document altered drug exposure and CBD-related sleepiness or sedation—not a proven memory-loss effect.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How can CBD change antidepressant metabolism?
- What do the citalopram and amitriptyline studies show?
- Could memory changes have another medication-related cause?
- What should you bring to a medication review?
How can CBD change antidepressant metabolism?
Enzymes help the body process medicines. One of them, CYP2C19, handles citalopram and some other drugs; a medicine processed by an enzyme is called its "substrate." The FDA's June 2025 Epidiolex label classifies prescription cannabidiol as a moderate CYP2C19 inhibitor. Inhibiting this enzyme can raise concentrations of CYP2C19-substrate medicines and increase their adverse-reaction risk.
The label advises clinicians to consider dose modification when appropriate. Higher exposure does not prove that cbd caused a new memory disorder. CBD-related sedation may make someone seem less alert or slower to respond, but that observation cannot distinguish sleepiness from impaired memory.
What do the citalopram and amitriptyline studies show?
In a study of 20 healthy adults, CBD at 2.5 mg per kilogram twice daily for 12 days increased total citalopram exposure by 43% and its peak concentration by 12%, according to U.S. FDA investigators. This provides direct evidence of a metabolism-based interaction, not proof that the combination causes memory loss. Citalopram is metabolized primarily by CYP2C19 and CYP3A4.
Its prescribing label limits dosing to 20 mg daily with CYP2C19 inhibitors because increased exposure raises the risk of QT prolongation and ventricular arrhythmias. The citalopram study was open-label and included healthy, nonsmoking adults ages 18 to 55. It does not establish the interaction's size or clinical effects in older adults, people with depression or liver disease, or those taking several medicines. A separate 12-person study found that a single 30-mg CBD dose increased amitriptyline exposure by 13% and its peak concentration by 17%. The researchers said the clinical importance remains unclear, illustrating why results should not be converted into a do-it-yourself dosing formula.
Could memory changes have another medication-related cause?
Memory impairment and confusion can be symptoms of SSRI-associated hyponatremia, meaning abnormally low blood sodium. The citalopram label maintained by DailyMed identifies older adults, people taking diuretics, and volume-depleted patients as higher-risk groups. Severe cases can progress to seizures, coma, or death.
New confusion or memory trouble therefore deserves more than an assumption that CBD is responsible. Ask whether sodium should be checked, particularly when one of those risk factors applies, and provide the timing of symptoms relative to any CBD or antidepressant change. Seizures, coma, or profound changes in awareness require emergency attention. Less severe new confusion still warrants prompt contact with the prescribing clinician rather than an unsupervised dose change.
What should you bring to a medication review?
The exact CBD product matters. The FDA's consumer guidance says nonprescription CBD products have not been evaluated for proper dosing, interactions, or safety.
Some may contain a different amount of CBD than the label states or contaminants such as THC. Bring or record: Ask the clinician or pharmacist whether the antidepressant depends on CYP2C19, whether CBD could raise its concentration, and which adverse effects should trigger a dose review. For citalopram, also ask whether the CYP2C19-inhibitor dose limit and heart-rhythm risk apply; for confusion or memory impairment, ask specifically whether blood sodium should be assessed.
- The product name and a photo of its ingredient label
- The CBD amount, route, frequency, and time of each dose
- The antidepressant name, dose, and dosing schedule
- Every other medicine, including any diuretic
- When the memory change, confusion, or unusual sleepiness began
